Data / adsl

ADaM · adsl

Subject-level analysis dataset

One record per subject: demographics, the study's own population flags, baseline measures, treatment and disposition. The denominator for every display.

Domain
ADaM
Source
vendored file, prepared by the pipeline
Lane
the study's own package (phuse-org/phuse-scripts)
Upstream path
data/adam/cdiscpilot01/adsl.xpt
Blob SHA-1
56e04ac80dab0d9bca3b48296a2c1eac654ccfb3
SHA-256
c5139f873a93ef6add77bc4297beb6460a398bbdd036874382a9f39dfc92091d
Bytes
114640
Vendored file
pipeline/inst/extdata/phuse-cdiscpilot01/adsl.xpt.gz gz e01b4be
Prepared rows
254
Prepared hash
b022f78 / 70c7278 / 1f6fa03 / 3139478
Read by
30 displays
Inputs
Function
Outputs
  • prepared frame254 rows · b022f78 / 70c7278 / 1f6fa03 / 3139478
  • 30 displayscomputed from it

Derivations and notes

The preparation layer's derivations are documented in the contracts, §4.

Read by

Every display whose current iteration names this dataset in its ARD's provenance envelope, with the row count and hash that iteration recorded for the prepared frame.

DisplayIterationRowsPrepared hashARD hash
Time to Dermatologic Event by Treatment Group f-derm-time-to-eventv00225470c7278dae95ac
Subject Disposition f-dispositionv0012543139478700d5e7
Listing of Serious Adverse Events l-ae-seriousv00325470c7278cde8256
Treatment-Emergent Adverse Events by System Organ Class and Preferred Term t-ae-commonv00425470c7278adf6d63
Incidence of Treatment Emergent Adverse Events by Treatment Group t-ae-incidencev007254b022f78091de51
Overview of Treatment-Emergent Adverse Events t-ae-overviewv00325470c7278c428956
CIBIC+ — Categorical Analysis — LOCF t-cibic-categoricalv00225470c72784847131
CIBIC+ — Summary at Week 16 — LOCF t-cibic-week16v00225470c72784f25a6b
Primary Endpoint Analysis: CIBIC+ — Summary at Week 24 — LOCF t-cibic-week24v00425470c7278a8f78f3
CIBIC+ — Summary at Week 8 — LOCF t-cibic-week8v00225470c72783073ee5
Summary of Concomitant Medications t-conmedsv003254313947895799f7
Demographic and Baseline Characteristics t-demographicsv007254b022f7887af027
Subject Disposition t-dispositionv00325470c72785a073a0
ADAS-Cog (11) - Repeated Measures Analysis of Change from Baseline to Week 24 t-eff-adas-mmrmv0042541f6fa038953a87
ADAS-Cog (11) - Mean and Mean Change from Baseline over Time t-eff-adas-overtimev00225470c7278ae89465
ADAS-Cog (11) - Change from Baseline to Week 16 - LOCF t-eff-adas-wk16v00225470c7278dd7d1cd
Primary Endpoint Analysis: ADAS-Cog (11) - Change from Baseline to Week 24 - LOCF t-eff-adas-wk24v00225470c72786e4dd40
ADAS-Cog (11) - Change from Baseline to Week 24 - Completers at Week 24, Observed Cases, Windowed t-eff-adas-wk24-completersv00225470c72789c9aef7
ADAS-Cog (11) - Change from Baseline to Week 24 in Female Subjects - LOCF t-eff-adas-wk24-femalev00225470c727892e3885
ADAS-Cog (11) - Change from Baseline to Week 24 in Male Subjects - LOCF t-eff-adas-wk24-malev00225470c7278bf57631
ADAS-Cog (11) - Change from Baseline to Week 8 - LOCF t-eff-adas-wk8v00225470c7278ec13102
Mean NPI-X Total Score from Week 4 through Week 24 - Windowed t-eff-npix-meanv00325470c7278670210c
Summary of End of Study Data t-end-of-studyv00325470c72784969678
Extent of Exposure to Study Drug t-exposurev00425470c7278de9e7ac
Summary of Populations t-populationsv00325470c7278a78a73c
Incidence of Treatment Emergent Serious Adverse Events by Treatment Group t-sae-incidencev006254313947894a983c
Summary of Number of Subjects By Site t-subjects-by-sitev0022541f6fa036887f57
Summary of Vital Signs at Baseline and End of Treatment t-vitalsv00225470c727880334ea
Summary of Vital Signs Change from Baseline at End of Treatment t-vitals-changev00225470c72784a0f857
Summary of Weight and Weight Change from Baseline at End of Treatment t-weightv004254b022f7839d684c